FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283588637> ?p ?o ?g. }

• W4283588637 endingPage "3179" @default.
• W4283588637 startingPage "3169" @default.
• W4283588637 abstract "No standard options existed for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer that progresses after second-line trastuzumab emtansine therapy before 2020. The purpose of this study was to examine the efficacy of pertuzumab retreatment after disease progression following pertuzumab-containing therapy for HER2-positive locally advanced or metastatic breast cancer for the first time. This randomized, open-label, multicenter phase III trial was undertaken in 93 sites in Japan. Eligible patients with HER2-positive breast cancer who had received pertuzumab, trastuzumab, and chemotherapy as first- and/or second-line therapy were randomly assigned (1:1) to: (i) pertuzumab, trastuzumab, and physician's choice chemotherapy (PTC), or (ii) trastuzumab and physician's choice chemotherapy (TC). The primary end-point was investigator-assessed progression-free survival (PFS). Between August 1, 2015 and December 31, 2018, 219 patients were randomized to PTC (n = 110) or TC (n = 109). Median follow-up was 14.2 months (interquartile range, 9.0-22.2), and median PFS was 5.3 months (95% confidence interval [CI], 4.0-6.6) with PTC and 4.2 months (95% CI, 3.2-4.8) with TC (stratified hazard ratio 0.76 [95% CI upper limit 0.967]; p = 0.022). Progression-free survival was improved by adding pertuzumab in all prespecified subgroups. The PTC arm showed a trend towards better overall survival and duration of response, but similar objective response and health-related quality of life. The incidence of treatment-related adverse events was similar between groups except for diarrhea. Pertuzumab retreatment contributes to disease control for HER2-positive locally advanced or metastatic breast cancer previously treated with pertuzumab-containing regimens." @default.
• W4283588637 created "2022-06-28" @default.
• W4283588637 creator A5001005844 @default.
• W4283588637 creator A5008549101 @default.
• W4283588637 creator A5008946028 @default.
• W4283588637 creator A5015450747 @default.
• W4283588637 creator A5019325551 @default.
• W4283588637 creator A5024725726 @default.
• W4283588637 creator A5025769245 @default.
• W4283588637 creator A5027634537 @default.
• W4283588637 creator A5036168618 @default.
• W4283588637 creator A5041726660 @default.
• W4283588637 creator A5056628460 @default.
• W4283588637 creator A5057720295 @default.
• W4283588637 creator A5061220478 @default.
• W4283588637 creator A5064748731 @default.
• W4283588637 creator A5065550886 @default.
• W4283588637 creator A5067189124 @default.
• W4283588637 creator A5069272944 @default.
• W4283588637 creator A5071117344 @default.
• W4283588637 creator A5073950448 @default.
• W4283588637 creator A5084823182 @default.
• W4283588637 creator A5088924059 @default.
• W4283588637 creator A5091245889 @default.
• W4283588637 date "2022-07-23" @default.
• W4283588637 modified "2023-10-07" @default.
• W4283588637 title "Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)" @default.
• W4283588637 cites W1857624176 @default.
• W4283588637 cites W1971267920 @default.
• W4283588637 cites W1973555911 @default.
• W4283588637 cites W1981701117 @default.
• W4283588637 cites W2077880074 @default.
• W4283588637 cites W2095861620 @default.
• W4283588637 cites W2104239861 @default.
• W4283588637 cites W2120627364 @default.
• W4283588637 cites W2123591186 @default.
• W4283588637 cites W2137086207 @default.
• W4283588637 cites W2139135964 @default.
• W4283588637 cites W2139444209 @default.
• W4283588637 cites W2143651667 @default.
• W4283588637 cites W2148962667 @default.
• W4283588637 cites W2156036657 @default.
• W4283588637 cites W2159967578 @default.
• W4283588637 cites W2165003903 @default.
• W4283588637 cites W2166199281 @default.
• W4283588637 cites W2278216532 @default.
• W4283588637 cites W2373606074 @default.
• W4283588637 cites W2551315898 @default.
• W4283588637 cites W2561530600 @default.
• W4283588637 cites W2609953159 @default.
• W4283588637 cites W2616596696 @default.
• W4283588637 cites W2624590002 @default.
• W4283588637 cites W2640246504 @default.
• W4283588637 cites W2833120298 @default.
• W4283588637 cites W2902218997 @default.
• W4283588637 cites W2918012424 @default.
• W4283588637 cites W2990277815 @default.
• W4283588637 cites W2995808512 @default.
• W4283588637 cites W2996630100 @default.
• W4283588637 cites W3091438619 @default.
• W4283588637 cites W3123743675 @default.
• W4283588637 cites W4283588637 @default.
• W4283588637 doi "https://doi.org/10.1111/cas.15474" @default.
• W4283588637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35754298" @default.
• W4283588637 hasPublicationYear "2022" @default.
• W4283588637 type Work @default.
• W4283588637 citedByCount "6" @default.
• W4283588637 countsByYear W42835886372022 @default.
• W4283588637 countsByYear W42835886372023 @default.
• W4283588637 crossrefType "journal-article" @default.
• W4283588637 hasAuthorship W4283588637A5001005844 @default.
• W4283588637 hasAuthorship W4283588637A5008549101 @default.
• W4283588637 hasAuthorship W4283588637A5008946028 @default.
• W4283588637 hasAuthorship W4283588637A5015450747 @default.
• W4283588637 hasAuthorship W4283588637A5019325551 @default.
• W4283588637 hasAuthorship W4283588637A5024725726 @default.
• W4283588637 hasAuthorship W4283588637A5025769245 @default.
• W4283588637 hasAuthorship W4283588637A5027634537 @default.
• W4283588637 hasAuthorship W4283588637A5036168618 @default.
• W4283588637 hasAuthorship W4283588637A5041726660 @default.
• W4283588637 hasAuthorship W4283588637A5056628460 @default.
• W4283588637 hasAuthorship W4283588637A5057720295 @default.
• W4283588637 hasAuthorship W4283588637A5061220478 @default.
• W4283588637 hasAuthorship W4283588637A5064748731 @default.
• W4283588637 hasAuthorship W4283588637A5065550886 @default.
• W4283588637 hasAuthorship W4283588637A5067189124 @default.
• W4283588637 hasAuthorship W4283588637A5069272944 @default.
• W4283588637 hasAuthorship W4283588637A5071117344 @default.
• W4283588637 hasAuthorship W4283588637A5073950448 @default.
• W4283588637 hasAuthorship W4283588637A5084823182 @default.
• W4283588637 hasAuthorship W4283588637A5088924059 @default.
• W4283588637 hasAuthorship W4283588637A5091245889 @default.
• W4283588637 hasBestOaLocation W42835886372 @default.
• W4283588637 hasConcept C119060515 @default.
• W4283588637 hasConcept C121608353 @default.
• W4283588637 hasConcept C126322002 @default.
• W4283588637 hasConcept C141071460 @default.
• W4283588637 hasConcept C143998085 @default.

• next